Abbott gets FDA OK for CLL test; Depuy uses 'unusual' approach in hip recall;

> Abbott ($ABT) has received FDA 510(k) clearance for the Vysis CLL FISH Probe Kit, a new in vitro diagnostic test to aid in determining the prognosis of patients with chronic lymphocytic leukemia. Abbott Molecular release

> Johnson & Johnson's ($JNJ) DePuy unit has hired Broadspire Services, which manages workers compensation and other medical claims on behalf of insurance companies and employers, to administer patient claims for out-of-pocket medical costs associated with the metal ASR hip system recall. And while some experts see it as an efficient way to outsource a process unrelated to making artificial hips, others see it as a company ploy to limit payments and gain control of medical records that could be used against patients in court. News

> Encision has named Fred Perner as its new president and CEO, effective Sept. 19. He succeeds Jack Serino, who is stepping down to pursue other interests. Encision release

> Quanterix, which makes an array system for molecular diagnostic tests, said it will move its systems to the next level through a partnership with Germany's Stratec Biomedical. Item

> The FDA has granted 510(k) clearance for NEC Display Solutions of America's 21.3-inch MultiSync MD215MG medical diagnostic display for the viewing of digital mammography images for diagnosis by physicians. NEC release

> Gestion de Negocios has named Welch Allyn to its list of "The Best Companies to Work For" in Mexico. This year's ranking placed the Tijuana factory, which opened 5 years ago, at number 38. Welch Allyn release

And Finally... Changes in cabin pressure may cause insulin pumps to deliver too much or too little medication, according to a report. Researchers are therefore recommending patients disconnect their pumps before take-off and after landing and ensure there are no air bubbles in the insulin before reconnecting it. However, an outside researcher said the concern might only apply to some diabetic patients. Story

Suggested Articles

The ADDF announced its second round of research awards, with a total of $6 million in new funding for diagnostic tests.

Takeda teamed up with Enzyre to develop an at-home diagnostic device that will help people with hemophilia determine their own coagulation status.

Foundation Medicine received a diagnostic approval from the FDA for selecting HR+/HER2- breast cancer patients for treatment with Novartis' Piqray.